Albertas Ulys
Overview
Explore the profile of Albertas Ulys including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
746
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ulys A, cerniauskiene A, Geavlete P, Larsen F, MacLean C, van Os S
Int Urol Nephrol
. 2024 Oct;
57(2):427-433.
PMID: 39428443
Purpose: To evaluate the efficacy and safety of teverelix in treatment naïve patients aged over 50 years with symptomatic benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), and...
2.
Saad F, Vjaters E, Shore N, Olmos D, Xing N, Pereira de Santana Gomes A, et al.
J Clin Oncol
. 2024 Sep;
42(36):4271-4281.
PMID: 39279580
Purpose: For patients with metastatic hormone-sensitive prostate cancer (mHSPC), delaying progression to castration-resistant disease is important not only for overall survival (OS) but also for patients' quality of life. Darolutamide...
3.
Zvirblyte J, Nainys J, Juzenas S, Goda K, Kubiliute R, Dasevicius D, et al.
Commun Biol
. 2024 Jun;
7(1):780.
PMID: 38942917
Clear cell renal cell carcinoma (ccRCC) is the most prevalent form of renal cancer, accounting for over 75% of cases. The asymptomatic nature of the disease contributes to late-stage diagnoses...
4.
Ulys A, Jankevicus F, Jievaltas M, Venckus R, Auskalnis S, Kardelis Z, et al.
Prostate
. 2024 Feb;
84(6):584-598.
PMID: 38311868
Background: Teverelix drug product (DP) is a novel injectable gonadotropin-releasing hormone antagonist. Methods: An adaptive phase 2, open-label, multicenter trial was conducted in patients with advanced prostate cancer to evaluate...
5.
Januskevicius T, Vaicekauskaite I, Sabaliauskaite R, Matulevicius A, Vezelis A, Ulys A, et al.
Medicina (Kaunas)
. 2024 Jan;
60(1).
PMID: 38256334
: Germline DNA damage response (DDR) gene mutations correlate with increased prostate cancer (PCa) risk and a more aggressive form of the disease. DDR mutation testing is recommended for metastatic...
6.
Zalimas A, Urbonas V, Dabkeviciene D, Purvaneckas J, Ulys A, Jarmalaite S
Anticancer Res
. 2023 Dec;
44(1):213-219.
PMID: 38160003
Background/aim: According to the European Society for Medical Oncology (ESMO) and National Comprehensive Cancer Network (NCCN) recommendations, sunitinib is one of the recommended regimens for favorable and intermediate-risk metastatic renal...
7.
Matulevicius A, Zukauskaite K, Gineikaite R, Dasevicius D, Trakymas M, Naruseviciute I, et al.
Prostate
. 2023 Aug;
83(16):1572-1583.
PMID: 37614027
Background: This study aimed to investigate the extent of field cancerization adjacent to index lesions in prostate cancer (PCa) by measuring DNA methylation of selected tumor suppressor genes in the...
8.
MacLean C, Ulys A, Jankevicius F, Saladzinskas Z, van Os S, Larsen F
Medicina (Kaunas)
. 2023 Apr;
59(4).
PMID: 37109639
Teverelix drug product (DP) is a gonadotropin-releasing hormone antagonist in development for the treatment of patients with prostate cancer in whom androgen deprivation therapy is indicated. The aim of this...
9.
Januskevicius T, Sabaliauskaite R, Dabkeviciene D, Vaicekauskaite I, Kulikiene I, Sestokaite A, et al.
Biomedicines
. 2023 Mar;
11(3).
PMID: 36979741
(1) Background: DNA damage response (DDR) pathway gene mutations are detectable in a significant number of patients with metastatic castration-resistant prostate cancer (mCRPC). The study aimed at identification of germline...
10.
Zalimas A, Kubiliute R, Zukauskaite K, Sabaliauskaite R, Trakymas M, Letautiene S, et al.
Int J Mol Sci
. 2022 Dec;
23(24).
PMID: 36555747
Active surveillance (AS) is the best strategy for small renal masses (SRMs) management; however, reliable methods for early detection and disease aggressiveness prediction are urgently needed. The aim of the...